Human ACAT inhibitory effects of shikonin derivatives from Lithospermum erythrorhizon

被引:44
作者
An, Sojin
Park, Yong-Dae
Paik, Young-Ki
Jeong, Tae-Sook [1 ]
Lee, Woo Song
机构
[1] KRIBB, Natl Res Lab Lipid Metab & Atherosclerosis, Taejon 305806, South Korea
[2] Univ Sci & Technol, Taejon 305806, South Korea
[3] Yonsei Univ, Dept Biochem, Seoul 131749, South Korea
关键词
ACAT inhibitor; shikonin derivatives;
D O I
10.1016/j.bmcl.2006.11.024
中图分类号
R914 [药物化学];
学科分类号
100701 [药物化学];
摘要
Three naphthoquinones were isolated by bioassay-guided fractionation from the CHCl3 extracts of roots of Lithospermum erythrorhizon. They were identified as acetylshikonin (1), isobutyrylshikonin (2), and (3-hydroxyisovalerylshikonin (3) on the basis of their spectroscopic analyses. The compounds 1-3 were tested for their inhibitory activities against human ACAT-1 (hACAT-1) or human ACAT-2 (hACAT-2). Compound 2 preferentially inhibited hACAT-2 (IC50 = 57.5 wM) than hACAT-1 (32% at 120 mu M), whereas compounds 1 and 3 showed weak inhibitory activities in both hACAT-1 and -2. To develop more potent hACAT inhibitor, shikonin derivatives (5-11) were synthesized by semi-synthesis of shikonin (4), which was prepared by hydrolysis of 1-3. Among them, compounds 5 and 7 exhibited the strong inhibitory activities against hACAT-1 and -2. Furthermore, we demonstrated that compound 7 behaved as a potent ACAT inhibitor in not only in vitro assay system but also cell-based assay system. (c) 2006 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1112 / 1116
页数:5
相关论文
共 20 条
[1]
A critical role for the histidine residues in the catalytic function of acyl-CoA:cholesterol acyltransferase catalysis:: Evidence for catalytic difference between ACAT1 and ACAT2 [J].
An, Sojin ;
Cho, Kyung-Hyun ;
Lee, Woo Song ;
Lee, He-Oh ;
Paik, Young-Ki ;
Jeong, Tae-Sook .
FEBS LETTERS, 2006, 580 (11) :2741-2749
[2]
INHIBITION OF ACYL-COA CHOLESTEROL O-ACYLTRANSFERASE REDUCES THE CHOLESTERYL ESTER ENRICHMENT OF ATHEROSCLEROTIC LESIONS IN THE YUCATAN MICROPIG [J].
BOCAN, TMA ;
MUELLER, SB ;
UHLENDORF, PD ;
BROWN, EQ ;
MAZUR, MJ ;
BLACK, AE .
ATHEROSCLEROSIS, 1993, 99 (02) :175-186
[3]
Acyl-coenzyme A: Cholesterol acyltransferase [J].
Chang, TY ;
Chang, CCY ;
Cheng, D .
ANNUAL REVIEW OF BIOCHEMISTRY, 1997, 66 :613-638
[4]
Roles of acyl-coenzyme A:cholesterol acyltransferase-1 and-2 [J].
Chang, TY ;
Chang, CCY ;
Lin, S ;
Yu, CJ ;
Li, BL ;
Miyazaki, A .
CURRENT OPINION IN LIPIDOLOGY, 2001, 12 (03) :289-296
[5]
Mass-production of human ACAT-1 and ACAT-2 to screen isoform-specific inhibitor: a different substrate specificity and inhibitory regulation [J].
Cho, KH ;
An, S ;
Lee, WS ;
Paik, YK ;
Kim, YK ;
Jeong, TS .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2003, 309 (04) :864-872
[6]
Acyl-CoA: Cholesterol acyltransferase inhibitor avasimibe reduces atherosclerosis in addition to its cholesterol-lowering effect in ApoE*3-Leiden mice [J].
Delsing, DJM ;
Offerman, EH ;
van Duyvenvoorde, W ;
van der Boom, H ;
de Wit, ECM ;
Gijbels, MJJ ;
van der Laarse, A ;
Jukema, JW ;
Havekes, LM ;
Princen, HMG .
CIRCULATION, 2001, 103 (13) :1778-1786
[7]
Selective ACAT Inhibitors as Promising Antihyperlipidemic, Antiatherosclerotic and Anti-Alzheimer Drugs [J].
Giovannoni, M. P. ;
Dal Piaz, V. ;
Vergelli, C. ;
Barlocco, D. .
MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2003, 3 (06) :576-584
[8]
The active site His-460 of human acyl-coenzyme A:cholesterol acyltransferase 1 resides in a hitherto undisclosed transmembrane domain [J].
Guo, ZY ;
Lin, S ;
Heinen, JA ;
Chang, CCY ;
Chang, TY .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (45) :37814-37826
[9]
IKENOYA M, 2006, ATHEROSCLEROSIS 0701
[10]
Kusunoki J, 2001, CIRCULATION, V103, P2604